Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Vemurafenib in BRAF+ Malignancies
NCT02441465Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vemurafenib in melanoma and cancer, sponsored by Roche. Primary endpoints: Area Under the Concentration-Time Curve of 14C-Labeled Vemurafenib From Time 0 to Last Measurable Concentration at Day 21, Area Under the Concentration-Time Curve of 14C-Labeled Vemurafenib From Time 0 to Infinity at Day 21 and 8 more. Started Aug 2015; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanomacancer
Beyond the preview
Go deeper on NCT02441465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441465.